NCT00905047 2026-03-13
COLOCROSS
Centre Oscar Lambret
Phase 3 Completed
Clinical Trials
560 trialsNCT00102011 2026-03-09
00-046
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
NCT07437573 2026-02-27
KLASS-09
Korea University Guro Hospital
Phase 3 Completed
NCT01013649 2026-02-23
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT02956876 2026-02-06
INCISIVE
University Hospital, Rouen
Phase 3 Completed
NCT03713593 2026-02-05
LEAP-002
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03867084 2026-02-04
KEYNOTE-937
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05177484 2026-01-30
PICoC
The Royal Wolverhampton Hospitals NHS Trust
Phase 3 Completed
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03377491 2026-01-21
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
NovoCure Ltd.
Phase 3 Completed
NCT04457297 2026-01-21
ALTAIR
National Cancer Center Hospital East
Phase 3 Completed
NCT00002968 2025-12-29
Edrecolomab in Treating Patients With Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02314182 2025-12-19
GRECCAR8
Hospices Civils de Lyon
Phase 3 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT03013010 2025-12-08
PREACT
Shanghai Cancer Hospital, China
Phase 3 Completed
NCT04835142 2025-12-05
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Completed
NCT03223376 2025-12-01
FRUTIGA
Hutchmed
Phase 3 Completed
NCT02967289 2025-11-17
IROCAS
UNICANCER
Phase 3 Completed
NCT04540211 2025-10-28
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT03269994 2025-10-21
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT02799212 2025-10-03
SOMAPROTECT01
Hospices Civils de Lyon
Phase 3 Completed
NCT03062358 2025-09-30
MK-3475-394
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01999634 2025-09-22
MTM-COLON-II
Centre Hospitalier Universitaire, Amiens
Phase 3 Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT01727388 2025-09-19
RIFIONA
Centre Hospitalier Universitaire, Amiens
Phase 3 Completed
NCT05064059 2025-09-17
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT05680870 2025-09-09
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
Tanta University
Phase 3 Completed
NCT04534075 2025-09-08
FIDURA
Sahlgrenska University Hospital
Phase 3 Completed
NCT04941300 2025-08-26
ColoRectal Cancer Screening for Southern California Community Health Centers
University of California, San Diego
Phase 3 Completed
NCT05625932 2025-08-22
PROTINCOL
Galician Research Group on Digestive Tumors
Phase 3 Completed
NCT04635423 2025-08-11
V503-064
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00680901 2025-08-07
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
Novartis
Phase 3 Completed
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT03434678 2025-07-30
Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT01815853 2025-07-03
Neo-CRAG
Sun Yat-sen University
Phase 3 Completed
NCT01804790 2025-06-12
Néofirinox
UNICANCER
Phase 3 Completed
NCT03750669 2025-05-13
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Completed
NCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT02764801 2025-05-06
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Thomas Jefferson University
Phase 3 Completed
NCT03957590 2025-05-02
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT00357682 2025-05-01
AspECT
University of Oxford
Phase 3 Completed
NCT04003636 2025-04-23
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed